- Home
- XERS vs PGC Comparison
XERS vs PGC Comparison
Compare XERS & PGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XERS
- PGC
- Stock Information
- Founded
- XERS 2005
- PGC 1921
- Country
- XERS United States
- PGC United States
- Employees
- XERS N/A
- PGC N/A
- Industry
- XERS Biotechnology: Pharmaceutical Preparations
- PGC Commercial Banks
- Sector
- XERS Health Care
- PGC Finance
- Exchange
- XERS Nasdaq
- PGC Nasdaq
- Market Cap
- XERS 444.0M
- PGC 475.7M
- IPO Year
- XERS 2018
- PGC N/A
- Fundamental
- Price
- XERS $3.09
- PGC $36.37
- Analyst Decision
- XERS Buy
- PGC Buy
- Analyst Count
- XERS 3
- PGC 1
- Target Price
- XERS $4.87
- PGC $32.00
- AVG Volume (30 Days)
- XERS 1.9M
- PGC 139.9K
- Earning Date
- XERS 11-08-2024
- PGC 10-22-2024
- Dividend Yield
- XERS N/A
- PGC 0.55%
- EPS Growth
- XERS N/A
- PGC N/A
- EPS
- XERS N/A
- PGC 1.82
- Revenue
- XERS $187,361,000.00
- PGC $209,728,000.00
- Revenue This Year
- XERS $20.35
- PGC N/A
- Revenue Next Year
- XERS $16.14
- PGC $20.06
- P/E Ratio
- XERS N/A
- PGC $20.00
- Revenue Growth
- XERS 22.72
- PGC N/A
- 52 Week Low
- XERS $1.69
- PGC $20.30
- 52 Week High
- XERS $3.64
- PGC $37.88
- Technical
- Relative Strength Index (RSI)
- XERS 49.74
- PGC 62.84
- Support Level
- XERS $2.82
- PGC $35.32
- Resistance Level
- XERS $3.12
- PGC $37.07
- Average True Range (ATR)
- XERS 0.18
- PGC 1.41
- MACD
- XERS -0.03
- PGC -0.20
- Stochastic Oscillator
- XERS 32.93
- PGC 75.68
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.
About PGC Peapack-Gladstone Financial Corporation
Peapack Gladstone Financial Corp provides banking services. It operates through two segments namely Banking, which involves the delivery of loans and deposits, and Peapack Private Division which includes asset management services. The banking segment includes commercial real estate, multifamily, residential and consumer lending, deposit generation, and internet banking services. Peapack Private includes asset management services for individuals and institutions; personal trust services, administrator, custodian and guardians, and other financial planning and advisory services.